Skip to main content
. 2022 Sep 24;11(19):5632. doi: 10.3390/jcm11195632

Table 2.

The primary endpoint was the composite outcome of death, need for mechanical ventilation (invasive or noninvasive or high-flow therapy via nasal cannula), and venous or arterial thrombosis within 30 days after randomization.

Primary Outcome Prophylaxis
Dose Tinzaparin 4500 IU/day
(N = 106)
Intermediate Dose
Tinzaparin
100 IU/kg/day
(N = 91)
Therapeutic Dose
Tinzaparin 175 UI/kg
(N = 103)
Absolute Difference
(* Intermediate Dose vs. Prophylactic Dose;
** Therapeutic Dose vs. Prophylactic Dose)
Risk Reduction
(* Intermediate Dose vs. Prophylactic Dose;
** Therapeutic Dose vs. Prophylactic Dose)
p-Value
Primary endpoint (day + 30).
N (%)
19 (17.9) 20 (22.0) 19 (18.4) * 1
** 0
* −4.0 (−7.2%, −15.3%)
** 0.5 (−9.9%, 10.9%)
0.769 1
Secondary outcomes
Death from any cause
N (%)
2 (1.9) 3 (3.3) 2 (1.9) * 1
** 0
* 1.4% (−3.1%, 5.9%)
** 0.05% (−3.7%, 3.8%)
0.79 2
Thrombotic event
N (%)
4 (3.8) 2 (2.2) 2 (1.9) * 2
** 2
* 1.6% (−3.1%, 6.3%)
** 1.9% (−2.5%, 6.3%)
0.74 2
ICU admission
N (%)
7 (6.6) 6 (6.6) 10 (9.7) * 1
** 3
* 0.01% (−6.9%, 6.9%)
** −3.1% (−4.3%, 10.5%)
0.63 1
High flow nasal cannula
N (%)
13 (12.3) 14 (15.4) 13 (12.6) * 1
** 0
* −3.1% (−6.6%, 12.8%)
** 0.4% (−8.6%, 9.3%)
0.78 1
Non invasive mechanical ventilation
N (%)
4 (3.8) 4 (4.4) 2 (1.9) * 0
** 2
* −0.6% (−4.9%, 6.2%)
** 1.8% (−2.7%, 6.3%)
0.67 2
Invasive ventilation
N (%)
1 (0.9) 2 (2.2) 3 (2.9) * 1
** 2
* −1.2% (−2.3%, 4.8%)
** −1.9% (−1.8%, 5.7%)
0.60 2
Progression WHO * scale, Median (Q1; Q3) −0.43 (−1; 0) 0.13 (−0.5; 1) 0.06 (0; 1) - - 0.69 3
Progression to adult respiratory distress syndrome by PaO2/FiO2 or SpO2/FiO2. N (%) 4 (3.8) 2 (2.2) 1 (1.0) - - 0.40 2
Length of hospital stay, Median (Q1; Q3) 10.0 (6.0; 17.0) 9.5 (6.0; 24.0) 11.0 (6.0; 14.0) - - 0.96 4
Major bleeding
N (%)
- - - - - -
Clinically relevant non major bleeding, N (%) 4 (3.8) 3 (3.3) 3 (2.9) * 1
** 1
* 0.5% (−4.7%, 5.6%)
** 0.9% (−4.0%, 5.7%)
1.00 2

* Primary endpoint was composite outcome of death, intensive care unit admission, need for mechanical ventilation (invasive or noninvasive or high-flow therapy via nasal cannula), and venous or arterial thrombosis within 30 days after randomization. Secondary outcomes were measured at 90 days after randomization. 1 Chi-square test p-value. 2 Fisher’s exact test p-value. 3 Wilcoxon’s test p-value. 4 Kruskal–Wallis’ test p-value. ** Therapeutic Dose vs. Prophylactic.